Antiacne Medications Pseudotumor Cerebri
Information source: University of Zurich
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Optic Disc Swelling
Intervention: Retinal nerve fibre layer measurement (Other)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Zurich Official(s) and/or principal investigator(s): Klara Landau, Prof MD, Study Chair, Affiliation: UniversityHospital, Zurich
Overall contact: Gregor Jaggi, MD, Phone: 0041 44 255 49 00, Email: gregor.jaggi@usz.ch
Summary
The exact incidence of optic disc swelling and idiopathic intracranial hypertension in
patients using antiacne medication is not known so far. The investigators hypothesize that
swelling of retinal nerve fibre layer measured by optical coherence tomography is more
frequent then assumed so far.
Clinical Details
Official title: Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment
Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Retinal nerve fibre layer
Detailed description:
Measurement of retinal nerve fibre layer using optical coherence tomography over a period of
6 to 9 months depending on exact antiacne medication.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Antiacne medication treatment indicated by dermatologist
- age > 18 years
- contraception if indicated
Exclusion Criteria:
- age < 18 years
Locations and Contacts
Gregor Jaggi, MD, Phone: 0041 44 255 49 00, Email: gregor.jaggi@usz.ch
University Hospital Zurich, Zurich, ZH 8091, Switzerland; Recruiting Isabelle Meneau, Email: isabelle.meneau@usz.ch Gregor Jaggi, MD, Principal Investigator
Additional Information
Study register Switzerland
Starting date: April 2014
Last updated: May 26, 2014
|